BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 12855632)

  • 1. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas.
    Rangel LB; Agarwal R; D'Souza T; Pizer ES; Alò PL; Lancaster WD; Gregoire L; Schwartz DR; Cho KR; Morin PJ
    Clin Cancer Res; 2003 Jul; 9(7):2567-75. PubMed ID: 12855632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor-deficient mutants.
    Aravindakshan J; Chen X; Sairam MR
    Neoplasia; 2006 Dec; 8(12):984-94. PubMed ID: 17217615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.
    Heinzelmann-Schwarz VA; Gardiner-Garden M; Henshall SM; Scurry J; Scolyer RA; Davies MJ; Heinzelmann M; Kalish LH; Bali A; Kench JG; Edwards LS; Vanden Bergh PM; Hacker NF; Sutherland RL; O'Brien PM
    Clin Cancer Res; 2004 Jul; 10(13):4427-36. PubMed ID: 15240533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.
    Shang X; Lin X; Manorek G; Howell SB
    Mol Pharmacol; 2013 Jan; 83(1):85-94. PubMed ID: 23053666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.
    Shang X; Lin X; Alvarez E; Manorek G; Howell SB
    Neoplasia; 2012 Oct; 14(10):974-85. PubMed ID: 23097631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tight junction formation in epithelial ovarian adenocarcinoma.
    Zhu Y; Sundfeldt K
    Acta Obstet Gynecol Scand; 2007; 86(8):1011-9. PubMed ID: 17653889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours.
    Zhu Y; Brännström M; Janson PO; Sundfeldt K
    Int J Cancer; 2006 Apr; 118(8):1884-91. PubMed ID: 16287068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
    Lu KH; Patterson AP; Wang L; Marquez RT; Atkinson EN; Baggerly KA; Ramoth LR; Rosen DG; Liu J; Hellstrom I; Smith D; Hartmann L; Fishman D; Berchuck A; Schmandt R; Whitaker R; Gershenson DM; Mills GB; Bast RC
    Clin Cancer Res; 2004 May; 10(10):3291-300. PubMed ID: 15161682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
    Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
    Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential roles of claudin-3 and claudin-4 in ovarian cancer management.
    Uthayanan L; El-Bahrawy M
    J Egypt Natl Canc Inst; 2022 Jun; 34(1):24. PubMed ID: 35665865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of claudin 1, 3, and 4 during normal mammary gland development in the mouse.
    Blanchard AA; Watson PH; Shiu RP; Leygue E; Nistor A; Wong P; Myal Y
    DNA Cell Biol; 2006 Feb; 25(2):79-86. PubMed ID: 16460231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors.
    Yuan X; Lin X; Manorek G; Kanatani I; Cheung LH; Rosenblum MG; Howell SB
    Mol Cancer Ther; 2009 Jul; 8(7):1906-15. PubMed ID: 19567823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells.
    D'Souza T; Agarwal R; Morin PJ
    J Biol Chem; 2005 Jul; 280(28):26233-40. PubMed ID: 15905176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derepression of CLDN3 and CLDN4 during ovarian tumorigenesis is associated with loss of repressive histone modifications.
    Kwon MJ; Kim SS; Choi YL; Jung HS; Balch C; Kim SH; Song YS; Marquez VE; Nephew KP; Shin YK
    Carcinogenesis; 2010 Jun; 31(6):974-83. PubMed ID: 20053926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells.
    Singh AB; Harris RC
    J Biol Chem; 2004 Jan; 279(5):3543-52. PubMed ID: 14593119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity.
    Agarwal R; D'Souza T; Morin PJ
    Cancer Res; 2005 Aug; 65(16):7378-85. PubMed ID: 16103090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion.
    Dahiya N; Becker KG; Wood WH; Zhang Y; Morin PJ
    PLoS One; 2011; 6(7):e22119. PubMed ID: 21789222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.